Shijiazhuang Pharmaceutical Innovation Co., Ltd. (hereinafter referred to as "the Company") held the 22nd meeting of the 6th Board of Directors and the 17th meeting of the 6th Supervisory Board on March 19, 2025, and the 2024 Annual General Meeting of Shareholders on April 15, 2025. The meetings reviewed and approved the proposal on the use of part of the idle raised funds and self-owned funds for cash management. Without affecting the construction of the investment projects funded by the raised funds and the normal operation of the Company, the Company and its subsidiaries will use no more than RMB 800 million (including this amount) of idle raised funds and no more than RMB 800 million (including this amount) of self-owned funds for cash management, investing in low-risk, liquid principal-protected products (including structured deposits, large certificates of deposit, etc.). The usage period is valid for 12 months from the date of approval by the shareholders' meeting. During the validity period of the above-mentioned amount and resolution, the business can be conducted in a rolling manner. For specific details, please refer to the announcement disclosed on the Giant Tide Information Network (http://www.cninfo.com.cn) titled "Announcement on the Use of Part of Idle Raised Funds and Self-owned Funds for Cash Management" (Announcement No. 2025-019). The Company has conducted cash management according to the above resolution. Some products have now matured and been redeemed, and the specific situation is announced as follows:
1. Cash Management Product Redemption Situation
| No. | Entrusting Party | Trustee | Product Name | Product Type | Source of Funds | Subscription Amount (10,000 RMB) | Start Date | Maturity Date | Earnings (10,000 RMB) |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Shijiazhuang Pharmaceutical Group | China Everbright Bank Co., Ltd. Shijiazhuang Branch | 2025 Currency-linked Corporate Structured Deposit Customized Phase 11 Product | Principal-protected Floating Income | Idle Raised Funds | 2,500.00 | November 14, 2025 | February 14, 2026 | 10.00 |
2. Explanation of Related Relationships
The Company has no related relationships with the above-mentioned bank.
3. Approval Procedures
The proposal on the use of part of the idle raised funds and self-owned funds for cash management has been reviewed and approved by the 22nd meeting of the 6th Board of Directors, the 17th meeting of the 6th Supervisory Board, and the 2024 Annual General Meeting of Shareholders. The independent directors, supervisory board, and sponsor institution have all expressed clear agreement. The amount and duration of the cash management conducted by the Company are within the approval scope and do not require further submission for board or shareholder meeting review.